Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 7/20 | 0.55 |
| ▸ | TUBB | P07437 | 7/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 7/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 7/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 7/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 7/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 7/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 7/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 7/20 | 0.55 |
| ▸ | TUBA3E | Q6PEY2 | 7/20 | 0.55 |
| ▸ | TUBA1A | Q71U36 | 7/20 | 0.55 |
| ▸ | TUBA1C | Q9BQE3 | 7/20 | 0.55 |
| ▸ | TUBB6 | Q9BUF5 | 7/20 | 0.55 |
| ▸ | TUBB2B | Q9BVA1 | 7/20 | 0.55 |
| ▸ | TUBB1 | Q9H4B7 | 7/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Albendazole Oxide SCHEMBL321413 | 1.00 | LMNA (0.55) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| Albendazole Oxide SCHEMBL3175532 | 0.99 | LMNA (0.54) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL11662850 | 0.91 | LMNA (0.53) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| Albendazole Oxide SCHEMBL30580728 | 0.91 | LMNA (0.64) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| Albendazole Oxide SCHEMBL17968582 | 0.91 | LMNA (0.64) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| Albendazole Oxide SCHEMBL1649240 | 0.91 | LMNA (0.64) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| Albendazole Oxide SCHEMBL9370388 | 0.90 | LMNA (0.66) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10890981 | 0.88 | NPC1 (0.43) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL11266576 | 0.88 | LMNA (0.45) | LMNATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL11213713 | 0.86 | LMNA (0.47) | LMNATUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| EP-3923988-B1 | TRIAMTERENE OR NOLATREXED FOR USE IN THE TREATMENT OF PHENYLKETONURIA | SOM INNOVATION BIOTECH S A (ES) | 2025-04-30 | — | — | EP | disclosed |
| US-20250100947-A1 | NITROUS OXIDE INHIBITOR | HIS MAJESTY THE KING IN RIGHT OF NEW ZEALAND ACTING THROUGH THE MINISTRY FOR PRIMARY INDUSTRIES (NZ) | 2025-03-27 | — | — | US | disclosed |
| US-12257253-B2 | Triamterene or nolatrexed for use in the treatment of phenylketonuria | SOM INNOVATION BIOTECH, S.A. (ES) | 2025-03-25 | — | — | US | disclosed |
| CN-119405655-A | Albendazole solid dispersant, and preparation method and application thereof | 华南农业大学 | 2025-02-11 | — | — | CN | disclosed |
| CN-118948779-A | Albendazole nano-crystal with high bioavailability and preparation method thereof | 中国药科大学 | 2024-11-15 | — | — | CN | disclosed |
| CN-118908897-A | Albendazole nanocrystal and preparation method thereof | 中国药科大学 | 2024-11-08 | — | — | CN | disclosed |
| EP-4452907-A1 | NITROUS OXIDE INHIBITOR | His Majesty the King In Right of New Zealand Acting Through the Ministry for Primary Industries (NZ) | 2024-10-30 | — | — | EP | disclosed |
| CN-118715194-A | Nitrous oxide inhibitors | 新西兰国王陛下通过初级产业部 | 2024-09-27 | — | — | CN | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024172666-A1 | NITRIFICATION INHIBITOR | NEWTON PAUL CHARLES DUMMERE (NZ) | 2024-08-22 | — | — | WO | disclosed |
| EP-3607084-B1 | A METHOD FOR TESTING ANTIMICROBIAL SUSCEPTIBILITY | UNIV WESTERN AUSTRALIA (AU) | 2024-05-01 | — | — | EP | disclosed |
| WO-2023121484-A1 | NITROUS OXIDE INHIBITOR | NEWTON PAUL CHARLES DUMMERE (NZ) | 2023-06-29 | — | — | WO | disclosed |
| CN-116297362-A | High-sensitivity, rapid and visual method for detecting albendazole and albendazole sulfoxide residues in animal-derived food | 湖北工业大学 | 2023-06-23 | — | — | CN | disclosed |
| US-20230181463-A1 | OLEOGEL AND OLEOPASTE COMPOSITIONS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-15 | — | — | US | disclosed |
| CN-115919774-A | Magnetic targeting nano albendazole liposome and preparation method thereof | 新疆医科大学第一附属医院 | 2023-04-07 | — | — | CN | disclosed |
| CN-114224834-B | Albendazole nano suspension with high bioavailability and preparation method thereof | 沈阳伟嘉生物技术有限公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220133726-A1 | TRIAMTERENE OR NOLATREXED FOR USE IN THE TREATMENT OF PHENYLKETONURIA | SOM INNOVATION BIOTECH, S.A. (ES) | 2022-05-05 | — | — | US | disclosed |
| CN-114224834-A | Albendazole nano suspension with high bioavailability and preparation method thereof | 沈阳伟嘉生物技术有限公司 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133726-A1 | TRIAMTERENE OR NOLATREXED FOR USE IN THE TREATMENT OF PHENYLKETONURIA | TPMT, MPST, SLC5A6 | LMNA 3111/4885TUBB4A 1954/4885TUBB 1700/4885 |
| US-20230181463-A1 | OLEOGEL AND OLEOPASTE COMPOSITIONS AND USES THEREOF | RAB5IF, OTC, LIPA | LMNA 3385/4885TUBB4A 305/4885TUBB 293/4885 |
| US-12257253-B2 | Triamterene or nolatrexed for use in the treatment of phenylketonuria | TPMT, MPST, SLC5A6 | LMNA 3111/4885TUBB4A 1954/4885TUBB 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.